Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGFR1/2 Vaccine + UFT/UZEL in Refractory Colorectal Cancer
NCT00677612Phase 2Terminated
- Sponsor
- The University of Tokyo
- Start
- May 2008
- Primary completion
- Mar 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LY6K + VEGFR1 + VEGFR2, elpamitide in colorectal cancer (CRC), sponsored by The University of Tokyo. Started May 2008; status: terminated.
02
Drugs
LY6K + VEGFR1 + VEGFR2elpamitide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00677612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00677612.